comparemela.com
Home
Live Updates
Aldeyra Therapeutics stock surges as reproxalap for allergic conjunctivitis trial meets primary endpoint : comparemela.com
Aldeyra Therapeutics stock surges as reproxalap for allergic conjunctivitis trial meets primary endpoint
Aldeyra Therapeutics (NASDAQ:ALDX) announced on Thursday that its investigational new drug reproxalap ophthalmic solution for patients with allergic...
Related Keywords
Todd Brady ,
Drug Administration ,
Aldeyra Therapeutics ,
New Drug Application ,
Drug User Fee Act ,
comparemela.com © 2020. All Rights Reserved.